Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (NQ: ONCY )

0.9800 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncolytics Biotech Inc

< Previous 1 2 3 4 5 6 Next >
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials... 
Via FinancialNewsMedia
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Promising Results Continue to Develop Optimism in Fight Against Cancers
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 27, 2021 – USA News Group – There’s plenty of optimism surrounding the major medical breakthroughs targeting multiple types... 
Via FinancialNewsMedia
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,... 
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Enrollment in the first dose escalation is complete with no safety issues reported to date Trial is designed to accelerate pelareorep’s development in Asian territories such as China, the world’s... 
Via FinancialNewsMedia
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Is Oncolytics Biotech's GOBLET Study Making Headway in the Fight Against Pancreatic and Colorectal Tumors?
Photo by Lucas Vasques on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.... 
Via Benzinga
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at... 
Via FinancialNewsMedia
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s... 
Via FinancialNewsMedia
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins Company moving to full enrollment pending independent safety review Multi-center trial being... 
Via FinancialNewsMedia
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer... 
Via FinancialNewsMedia
Topics Death
Exposures Death
This Biotech Is Working With Pfizer, Merck KGaA, Roche, and Other Leaders To Develop a Better Standard of Care for Breast Cancer
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cancer is the... 
Via Benzinga
Promising Developments in Breast Cancer Treatments Ahead in 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against... 
Via FinancialNewsMedia
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 10, 2021 – USA News Group – Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as... 
Via FinancialNewsMedia
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the... 
Via FinancialNewsMedia
Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer
Dr. Heineman has over two decades of experience successfully leading clinical development programs and previously served as Oncolytics’ Global Head of Clinical Development and Operations SAN DIEGO, CA... 
Via FinancialNewsMedia
Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia Therapeutics
Palm Beach, FL – December 15, 2021 – FinancialNewsMedia.com News Commentary – Acute Myeloid Leukemia (AML) is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also... 
Via FinancialNewsMedia
Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting
Treatment with intravenous pelareorep plus azacitidine reduced tumor burden Treatment with pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses... 
Via FinancialNewsMedia
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options... 
Via FinancialNewsMedia
Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium
No safety concerns have been noted in any trial participants Trial builds on prior clinical data demonstrating pelareorep’s ability to reverse immunosuppressive tumor microenvironments and upregulate... 
Via FinancialNewsMedia
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 8, 2021 – USA News Group – Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit... 
Via FinancialNewsMedia
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
25 Stocks Moving in Friday's Pre-Market Session
Gainers iSpecimen Inc. (NASDAQ: ISPC) rose 56.9% to $16.00 in pre-market trading. The company recently announced it has been contracted to support new advanced research on COVID-... 
Via Benzinga
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
Exposures COVID-19 Product Safety
Earnings Scheduled For November 5, 2021
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEPC) is projected to report earnings for its third quarter. • Healthcare Trust (NYSE:HTA) is... 
Via Benzinga
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,... 
Via FinancialNewsMedia
Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming Peers
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 14, 2021 – USA News Group – Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3... 
Via FinancialNewsMedia
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.